Abstract Book

« Cohort Turnover and Productivity: The July Phenomenon in Teaching Hospitals | Main | Evaluating Appropriateness of Antibiotic Use for Children with Otitis Media in Rhode Island »

Date
Jun
05
2006

Cost-Effectiveness of Delivering Adult Influenza Vaccination in Non-Traditional Settings

Presenter:

Megan O'Brien

Authors:

Lisa Prosser, Megan O’Brien, Noelle-Angelique Molinari, Katherine Hohman, Kristin Nichol, Pascale Wortley, Mark Messonnier, Tracy Lieu

Chair: Noelle-Angelique M. Molinari; Discussant: Bo-Hyun Cho Mon June 5, 2006 15:30-17:00 Room 325

Despite the morbidity and mortality associated with influenza illness, vaccination coverage rates remain well below Healthy People 2010 goals for groups that are recommended to receive influenza vaccination. Non-traditional settings may represent an opportunity for boosting influenza immunization coverage rates for recommended adults. The objective of this project was to evaluate the cost-effectiveness of delivering inactivated influenza vaccinations to adults in non-traditional settings. A decision tree was developed to predict the costs and health effects of inactivated influenza vaccination in various settings compared with no vaccination. Non-traditional settings included in the analysis were (1) mass vaccination clinics that can be conducted at a variety of locations such as employer sites, retail stores, or pharmacies and (2) pharmacies that use pharmacists to deliver vaccinations. The traditional setting was defined as the physician office with a scheduled appointment for vaccination. Adults were stratified by age and risk status for influenza-related complications. Probabilities and costs (direct and opportunity) for uncomplicated influenza illness, outpatient visits, hospitalizations, deaths, vaccination and vaccine adverse events were based on primary and secondary data. Costs of vaccination in non-traditional settings were collected via telephone surveys with representatives of organizations that conduct mass vaccination clinics and pharmacies. Primary outcomes reported were $/influenza episode averted, $/hospitalization averted, and $/death averted. For healthy 18-49 year olds, cost per influenza episode averted for vaccination in the pharmacy setting was $140 (95% probability interval: cost saving - $1200), $260 (cost saving-$1800) in the mass vaccination setting, and $1150 ($390-$6200) in the traditional setting. Vaccination was more likely to be cost-saving as age increased. Cost-effectiveness ratios were more favorable for high-risk as compared with healthy adults in the same age group. Results were sensitive to assumptions regarding probability of influenza illness, costs of vaccination (including patient time costs), and vaccine effectiveness. Non-traditional settings may represent a more convenient setting for vaccination at comparable or better cost-effectiveness than the traditional physician office setting.

ASHEcon

3rd Biennial Conference: Cornell on June 20-23 2010

Welcome to ASHEcon

The American Society of Health Economists (ASHEcon) is a professional organization dedicated to promoting excellence in health economics research in the United States. ASHEcon is an affiliate of the International Health Economics Association (iHEA). ASHEcon provides a forum for emerging ideas and empirical results of health economics research.